Ercros SA
MAD:ECR
Intrinsic Value
Ercros SA engages in the manufacture and commercialization of chemical products. [ Read More ]
The intrinsic value of one ECR stock under the Base Case scenario is 4.45 EUR. Compared to the current market price of 3.5 EUR, Ercros SA is Undervalued by 21%.
Valuation Backtest
Ercros SA
Run backtest to discover the historical profit from buying and selling ECR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Balance Sheet Decomposition
Ercros SA
Current Assets | 209.4m |
Cash & Short-Term Investments | 39.1m |
Receivables | 58.9m |
Other Current Assets | 111.4m |
Non-Current Assets | 473.9m |
Long-Term Investments | 57.3m |
PP&E | 354.3m |
Intangibles | 20m |
Other Non-Current Assets | 42.3m |
Current Liabilities | 164m |
Accounts Payable | 90.9m |
Accrued Liabilities | 4.1m |
Short-Term Debt | 7.8m |
Other Current Liabilities | 61.2m |
Non-Current Liabilities | 156.2m |
Long-Term Debt | 99.5m |
Other Non-Current Liabilities | 56.7m |
Earnings Waterfall
Ercros SA
Revenue
|
1.1B
EUR
|
Cost of Revenue
|
-723.7m
EUR
|
Gross Profit
|
340.3m
EUR
|
Operating Expenses
|
-332.8m
EUR
|
Operating Income
|
7.5m
EUR
|
Other Expenses
|
12.2m
EUR
|
Net Income
|
19.8m
EUR
|
Free Cash Flow Analysis
Ercros SA
EUR | |
Free Cash Flow | EUR |
ECR Profitability Score
Profitability Due Diligence
Ercros SA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Ercros SA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
ECR Solvency Score
Solvency Due Diligence
Ercros SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Ercros SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ECR Price Targets Summary
Ercros SA
According to Wall Street analysts, the average 1-year price target for ECR is 4.64 EUR with a low forecast of 4.6 EUR and a high forecast of 4.78 EUR.
Shareholder Return
ECR Price
Ercros SA
Average Annual Return | 15.32% |
Standard Deviation of Annual Returns | 19.49% |
Max Drawdown | -53% |
Market Capitalization | 320m EUR |
Shares Outstanding | 91 436 200 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ercros SA engages in the manufacture and commercialization of chemical products. The company is headquartered in Barcelona, Barcelona and currently employs 1,321 full-time employees. The Company’s products are structured into three business lines: Businesses Associated to Chlorine, which comprises the production of chlorine, ethyl acetate, caustic soda, sodium hypochlorite, dichloroethane, chloromethane, sodium chlorate and caustic potash, polyvinyl chloride (PCV), as well as water disinfectants; Intermediate Chemicals, which produces formaldehyde, glues and resins for the fiberboard and plywood industries, and Pharmaceuticals, which comprises raw material and intermediate products used in the pharmaceutical industry. The firm owns such subsidiaries as Marcoating SLU, Gades Ltd and Ercekol AIE, among others. In April 2014, it sold Fosfatos de Cartagena SLU to Timab Iberica.
Contact
IPO
Employees
Officers
The intrinsic value of one ECR stock under the Base Case scenario is 4.45 EUR.
Compared to the current market price of 3.5 EUR, Ercros SA is Undervalued by 21%.